CEO & Scientific Co-Founder
Dr. Frederic Bard is the Scientific Founder of the company. He also serves as Director of Research at the Cancer Research Centre in Marseille, France.
Dr. Bard did his graduate work at Yale University, USA, and at the Ecole Normale Superieure of Lyon, France, where he obtained his PhD degree. During his postdoctoral work at the University of California San Diego from 2001 to 2006, he identified a collection of new genes essential for general protein secretion, called the TANGO genes.
In 2006, Dr. Bard started his research group at the Institute of Molecular and Cellular Biology (IMCB), A*STAR, Singapore. The glycosylation-driven tissue remodeling and the intervention to this process in treatment of cancer and arthritis were discovered and developed by his team at A*STAR.